Intensive care utilization in patients with end-stage liver disease: A population-based comparative study of cohorts with and without comorbid hepatocellular carcinoma in Taiwan

Jen-Kuei Peng,a,b,c*, Hao-Hsiang Changb,c, Irene J Higginson,a Wei Gaoa

a Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King’s College London, Address: Bessemer Road, London, SE5 9PJ, United Kingdom
b Department of Family Medicine, National Taiwan University College of Medicine, Address: No.1 Jen Ai Road, Section 1, Taipei 100, Taiwan
c Department of Family Medicine, National Taiwan University Hospital, Address: No.7, Chung Shan South Road, Taipei 100, Taiwan

Abstract

Background: End-of-life intensive care may be futile and can be a cause of distress to both patients and their families. This study aimed to understand the utilization of intensive care and its associated factors in patients with end-stage liver disease (ESLD) during terminal hospitalization.

Methods: Population-based retrospective cohort study using the National Health Institute Research Database of Taiwan. All adult patients with ESLD who died during their hospitalization in 2010–2013 were included.

Findings: Of the 14,247 patients with ESLD, the majority (60.8%) was comorbid with hepatocellular carcinoma (HCC). Patients with ESLD only were younger, more deprived, more alcohol-related, and less likely to receive palliative care prior to terminal hospitalization (6.6% vs 29.2% with HCC). Compared to patients with comorbid HCC, relatively more patients without HCC were admitted to ICU (59.6% vs 22.3%), receiving CPR (11.1% vs 4.3%) and mechanical ventilation (36.3% vs 12.5%) during terminal hospitalization. Etiology of alcoholic hepatitis, esophageal varices, septicemia, pneumonia and respiratory failure, and renal failure were associated with a higher probability of ICU admission (adjusted rate ratio (aRR) range: 1.09–2.09). Prior palliative care was associated with lower probability of ICU admission (aRR range: 0.24–0.38).

Interpretation: The intensive care utilization by patients with ESLD in their terminal hospitalization was substantial in Taiwan. Those who are not comorbid with HCC need more attention, especially in terms of their palliative care needs, choices regarding intensive care, and their healthcare utilization.

Funding: National Institute of Health Research Health Applied Research Collaboration (ARC) South London.

© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

End-stage liver disease (ESLD) is the final stage of liver disease when liver failure is irreversible and liver transplantation is the only curative treatment [1]. A global estimate reported it accounted for 2% of all deaths worldwide [2,3]. It is the seventh leading cause of death in Europe [4], and the 12th leading cause of death in the United States [5]. Compared to other terminal illness, it disproportionately affects younger age groups, which results in premature mortality, high loss of working years, as well as complex physical and psychosocial problems [6,7].

In Taiwan, ESLD is also a major cause of death and an important public health issue. Different from western countries, the leading etiology of liver disease in Taiwan is viral hepatitis (especially hepatitis B), rather than alcoholic hepatitis or non-alcoholic steatohepatitis [8–9]. Patients with hepatitis B-related cirrhosis have 1000 times higher risk of developing hepatocellular carcinoma (HCC) compared to those who are not carriers of hepatitis B surface antigen [10]. HCC is therefore a common comorbidity of patients with ESLD in Taiwan.

The priority of medical care for patients with ESLD is usually curative treatment rather than palliative care because these patients are younger and not seen to be at the end of life [6,11]. However, only a minority of these patients receive liver transplantation owing to organ shortages and strict eligibility criteria. The prognosis of ESLD is hard to determine, and some patients live prolonged periods of poor health, interrupted by repeated catastrophe, and die suddenly [11]. Owing to the lack of early consensus of goals of care and palliative care service,
Research in context

Evidence before this study

We searched three electronic databases, including Medline, Embase, and PsycINFO, using the search terms (“intensive care” OR “critical care”) AND “end stage liver disease”. No restriction on language was implemented. However, research evidence in this area was scarce, especially while these patients were approaching their end of lives. The utilization of intensive care and its associated factors in patients with end-stage liver disease during terminal hospitalization are worth exploring.

Added value of this study

In this population-based study of 14,247 decedents with end-stage liver disease, patients without hepatocellular carcinoma were significantly more likely to be admitted to intensive care unit than those with hepatocellular carcinoma (59.6% versus 22.3%). Prior palliative care was associated with a lower probability of intensive care utilization during terminal hospitalization.

Implication of all the available evidence

For patients with end-stage liver disease, those who were not comorbid with hepatocellular carcinoma need more attention especially in terms of their palliative care needs, choices regarding intensive care, and their healthcare utilization.

Data source

The NHIRD of Taiwan is a reliable resource of healthcare utilization data because of its universal coverage and comprehensive details of services. It consists of healthcare data from over 25 million enrollees, representing more than 99% of the entire population of Taiwan [23–27]. The accuracy of diagnosis of some major diseases in the NHIRD has been validated [23,28].

Patient cohorts

Our population of interest was all adult patients (18 years and older) with ESLD who died during their hospitalization between 2010 and 2013. Patients were identified as having ESLD by the code from Registry for Catastrophic Illness Patients Database (RCIPD), a subpart of the NHIRD. In Taiwan, once any major complication of decompensation occurs and becomes irreversible, the patients with ESLD can be registered in RCIPD by qualified gastroenterologists, hepatologists, or liver transplantation providers (mostly transplantation surgeons). After the registration, these patients are issued an ESLD Catastrophic Illness Card, which can be identified by the web-based electronic system during every outpatient visit or inpatient hospitalization and then recorded in the original claim data.

Patients were excluded if they had a diagnosis of cancer other than HCC [International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM): 155.0], if they had received liver transplantation, or if they were admitted for less than one day or more than 90 days.

Variables of Interest

The primary outcome was intensive care unit (ICU) admission during terminal hospitalizations. Secondary outcomes were cardiopulmonary resuscitation (CPR) and mechanical ventilation during terminal hospitalizations.

The explanatory variables were age (<45, 45–54, 55–64, 65–74, 75–84, 85+), sex (female, male), year of death (2010, 2011, 2012, 2013), income level (5 groups), region of residence (northern, middle, southern, eastern and offshore islands, and not mentioned), and reasons for terminal hospitalization. For each patient, the number of reasons for hospitalization could be single or multiple, from one (ESLD only), two (ESLD plus HCC or any other reason of interest) to a maximum of five in the dataset. The reasons we studied were either complications of liver cirrhosis (e.g. hepatic encephalopathy, esophageal varices, ascites, peritonitis, and hepatorenal syndrome) or the other most common diagnoses for hospitalization (≥ 5% of the whole study population), including: septicemia, pneumonia and respiratory failure, renal failure, and peptic ulcer disease. The income level was classified according to the Taiwan minimum monthly wage (17,280 New Taiwan Dollars [NTD]) and income quartiles of 2011 [29]. Level 1 was defined as lower than minimum monthly wage (17,280 NTD); level 2 was defined as between minimum wage and Q1 (25,348 NTD); level 3 was defined as between Q1 and Q2 (equal to median: 32,132 NTD); level 4 was defined as between Q2 and Q3 (32,132 NTD); level 5 was defined as not less than Q3. For those who had no income (mostly dependent on a family member paying for the insurance, that is, the insurer), we considered the insurers’ income instead. Patients with neither income nor any insurer were classified as lowest income level (level 1).

In addition, we traced back any claim in the year before the terminal hospitalization to identify patients’ etiology of ESLD (viral, alcoholic, mixed viral and alcoholic, and others or not mentioned), number of comorbidities (using the items from Charlson index [30]), with ESLD and HCC deducted), and prior palliative care (palliative care unit admission or shared care by palliative care teams). In Taiwan, all the palliative care units are hospital-based and covered by

Methods

Study design

We did a nationwide retrospective cohort study, using the National Health Institute Research Database (NHIRD) of Taiwan, 2010–2013. The study is reported according to the STROBE guidelines [22].

these patients are at risk of receiving more futile intensive care and aggressive treatments. Intensive care is not always beneficial to patients at the end of life [12,13]. It may cause psychological distress to the patients and their family, and may deprive them of the companionship of their close relatives [14–17]. Although research increasingly suggests that palliative care should be integrated into the care of patients with ESLD, there is still insufficient evidence of palliative care intervention in these patients in terms of its association with healthcare utilization or outcomes [18–20].

Since September 2009, the National Health Insurance of Taiwan has expanded its palliative care coverage from advanced cancers and motor neuron diseases to eight non-cancer diseases, including ESLD [21]. The utilization of palliative care in patients with ESLD can therefore be identified and analyzed using the nationwide routinely collected health data – the National Health Institute Research Database (NHIRD). It provides a valuable opportunity to understand how these patients utilize intensive care and palliative care, especially during the end of their lives. The change in healthcare utilization after the policy implementation in 2009 is also noteworthy. In addition, we hypothesized that the two groups (“ESLD without HCC” versus “ESLD with HCC”) might be different in socio-demographic and clinical characteristics, so we explored and checked these differences.

The aims of this study are to investigate the utilization of intensive care in patients with ESLD in Taiwan, to explore the factors associated with intensive care utilization during terminal hospitalization, and to understand the difference between patients with and without comorbid HCC for targeted improvement.

Methods

Study design

We did a nationwide retrospective cohort study, using the National Health Institute Research Database (NHIRD) of Taiwan, 2010–2013. The study is reported according to the STROBE guidelines [22].
the National Health Insurance. For those who are in need of palliative care but unable to be admitted to the palliative care units, an outreach service can be provided to them by palliative care teams, which is called “shared care”. This kind of service is also covered by the National Health Insurance of Taiwan. No matter palliative care unit admission or shared care is introduced to the patients and their family, several key issues would be discussed, including: patients’ perception of the disease, goals of care, the ways to relieve total suffering, and the choices of treatments (including but not limited to do-not-resuscitate orders, withdrawing/withholding certain treatments, advance care planning).

Statistical Analysis

Numerical data was summarized using mean (standard deviation) or median (interquartile range) according to its distribution. Counts and percentages were used to describe categorical data. Bivariate analyses were performed to check the difference of socio-demo-graphics, clinical characteristics, and utilization between patients with and without HCC. Student’s t-test was applied to compare “age at death” because this variable was near-normal distribution. Wilcoxon rank-sum test was applied to compare “length of terminal hospitalization” since this variable was not normally distributed (relatively right skewed). As for the other variables, the Chi-square test was applied.

For factors associated with ICU admission, modified Poisson regression models with robust variance were applied [31]. Univariate analyses were firstly performed to check if there was an association between each individual explanatory variables and ICU admission, and the unadjusted rate ratio was obtained. Those which were statistically significant in univariate analysis (p < 0.05) were included in the multivariate modeling to evaluate the multiple adjusted associations. We used the threshold of 0.05 to select variables because with this scale of sample size, a statistical test might be powered to detect even very weak association. The length of stay of terminal hospitalization was treated as a confounding variable and was adjusted in the models. The strength of association was measured using the adjusted rate ratio (aRR), estimated from multivariable models [32–34]. For factors associated with CPR and mechanical ventilation, similar methods were used.

Potential interactions between variables were tested, and sensitivity analyses were carried out by running separate models omitting one of the concerned variables or taking interactions into considerations. We used Stata/SE 14 (STATA, College Station, TX) for all analyses.

Ethics approval and consent to participate

This study was approved by the ethical review of the Research Ethics Committee D of the National Taiwan University Hospital and the National Health Research Institutes, Taiwan. (NTUH-REC No.201508023 W, NHIRD-105–002) This study was based on fully anonymized records and therefore no personal data could be identified.

This study is based in part on data from the NHIRD provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of National Health Insurance Administration, Ministry of Health and Welfare or National Health Research Institutes of Taiwan.

Data Statement

According to the data agreement we signed with the National Health Research Institutes of Taiwan, we are not allowed to share our data.

Role of funding

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Results

Between 2010 and 2013, a total of 14,847 terminal hospitalizations of adult patients with ESLD were identified. There were 383 hospitalizations (2.6%) less than one day and 144 hospitalizations (1.0%) more than 90 days. In addition, 73 patients received liver transplantation (0.5%) prior to the terminal hospitalizations. After excluding these 600 patients, a total of 14,247 patients were kept in this study finally. The mean age of death was 63.6 (standard deviation [SD] 13.6). Among them, 8664 (60.8%) patients had a comorbid HCC, and 5583 (39.2%) did not. There were more men (69.4%) than women (30.6%). The income level of these decedents was extremely low. A total of 9686 patients (68.0%) was diagnosed as having viral hepatitis. The annual deaths decreased steadily from 3925 in 2010 to 2904 in 2013. The percentage of patients utilizing palliative care in the year before the terminal hospitalization increased gradually, from 10.3% in 2010 to 30.0% in 2013. Apart from ESLD and HCC, hepatic encephalopathy was the most common reason for admission (30.2%), followed by sepsis (29.9%), pneumonia and respiratory failure (28.1%), and esophageal varices (20.9%).

The socio-demographic and clinical characteristics between ESLD patients with and without comorbid HCC were different (Table 1). Those who died without HCC were younger (60.0[SD 14.3] vs 66.0[SD 12.1]) and more deprived. While viral hepatitis accounted for 80% of patients with HCC, alcoholic hepatitis was the main cause of patients without HCC (54.3%). Patients without HCC were less likely to receive palliative care prior to terminal hospitalization (6.0% vs 29.2%). The length of stay of terminal hospitalization was longer in patients without HCC (median: 14 vs 12).

The results of ICU admission and other outcomes of interest are shown in Table 2. The intensive care utilization of patients with ESLD in their terminal hospitalization was substantial. Relatively more patients without HCC were admitted to ICU than those with HCC (59.6% versus 22.3%, risk ratio 2.67 [95% confidence interval: 2.56–2.80]). They also had a longer length of stay in ICU (median: 6 vs 4, p < 0.001). Similarly, relatively more patients without HCC were receiving CPR (11.1% vs 4.3%, risk ratio 2.57[2.27–2.91]) and mechanical ventilation (36.3% vs 12.5%, risk ratio 2.91[2.73–3.11]) during terminal hospitalization, compared to patients with comorbid HCC.

The trends of ICU admission during terminal hospitalization by the status of comorbid HCC in 2010–2013 are shown in Fig. 1. The ICU admission rate decreased gradually in those who had ESLD only, while it decreased steadily between 2010 and 2012 and slightly increased in 2013 in those who had comorbid HCC. Meanwhile, the palliative care utilization in the year before terminal hospitalization increased markedly in both groups, although the proportion is still very low in those who had ESLD only. (Fig. 2)

Table 3 demonstrates the factors associated with ICU admission in patients with ESLD in their terminal hospitalization. Esophageal varices (aRR 1.13 [95% confidence interval 1.08–1.18] in ESLD only group; aRR 1.78 [1.64–1.92] in ESLD plus HCC group), sepsis (aRR 1.12 [1.07–1.16]; 1.36 [1.25–1.48]), pneumonia and respiratory failure (aRR 1.26 [1.21–1.31]; 2.89 [1.94–2.25]), and renal failure (aRR 1.10 [1.05–1.15]; 1.38 [1.25–1.52]) were associated with higher probability of ICU admission in both groups. In addition, etiology of alcoholic hepatitis (aRR 1.09 [1.02–1.16]; 1.29 [1.14–1.46]) and residential area as middle part of Taiwan (aRR 1.06 [1.00–1.12]; 1.29 [1.17–1.42]) were associated with a higher chance of ICU admission. On the contrary, prior palliative care (in the year before terminal hospitalization) was significantly associated with lower
Table 1
Socio-demographic and clinical characteristics* of study population (N = 14,247).

| Variable                        | ESLD only | ESLD + HCC | p-value |
|--------------------------------|-----------|------------|---------|
| Number (%)                     | 5583 (39.2%) | 8664 (60.8%) | <0.001 |
| Age median (SD)                | 60.0 (14.3) | 66.0 (12.1) | <0.001 |
| Age group (<45)                | 923 (16.5) | 388 (4.5) | <0.001 |
| 45–54                          | 1319 (23.6) | 1315 (15.2) | <0.001 |
| 55–64                          | 1242 (22.3) | 2283 (26.4) | <0.001 |
| 65–74                          | 1083 (19.4) | 2482 (28.7) | <0.001 |
| 75–84                          | 846 (15.2) | 1807 (20.9) | <0.001 |
| 85+                            | 170 (3.0) | 389 (4.5) | <0.001 |
| Sex                            |            |            | 0.020  |
| Female                         | 1770 (31.7) | 2587 (29.9) | <0.001 |
| Male                           | 3813 (68.3) | 6077 (70.1) | <0.001 |
| Year of death                  |            |            | 0.030  |
| 2010                           | 1598 (28.6) | 2327 (26.9) | <0.001 |
| 2011                           | 1518 (27.2) | 2317 (26.7) | <0.001 |
| 2012                           | 1384 (24.8) | 2199 (25.4) | <0.001 |
| 2013                           | 1083 (19.4) | 1821 (21.0) | <0.001 |
| Income level                   |            |            | <0.001 |
| 1 (less than minimum wage)     | 1780 (31.9) | 2115 (24.4) | <0.001 |
| 2 (minimum wage - Q1)          | 2678 (48.0) | 4302 (49.7) | <0.001 |
| 3 (Q1 - Q2)                    | 343 (6.1) | 591 (6.8) | <0.001 |
| 4 (Q2 – Q3)                    | 358 (6.4) | 606 (7.0) | <0.001 |
| 5 (more than Q3)               | 424 (7.6) | 1048 (12.1) | <0.001 |
| Region of residence            |            |            | <0.001 |
| Northern Taiwan                | 1694 (30.3) | 2879 (33.2) | <0.001 |
| Southern                      | 1255 (22.5) | 1527 (17.6) | <0.001 |
| Eastern and offshore islands   | 2073 (37.1) | 3797 (43.8) | <0.001 |
| Not mentioned                  | 278 (5.1) | 279 (3.2) | <0.001 |
| Not mentioned or others        |            |            | <0.001 |
| Comorbidity (ESLD deducted)    |            |            | <0.001 |
| 0                              | 777 (13.9) | 0 (due to HCC+) | <0.001 |
| 1                              | 1800 (32.2) | 1946 (22.5) | <0.001 |
| 2                              | 1611 (28.9) | 3406 (39.3) | <0.001 |
| 3                              | 885 (15.9) | 2127 (24.6) | <0.001 |
| 4+                             | 510 (9.1) | 1185 (13.7) | <0.001 |
| LOS of terminal hospitalization (days) median (IQR) range | | |
| Prior palliative care          |            |            | <0.001 |
| No                             | 5246 (94.0) | 6136 (70.8) | <0.001 |
| Yes                            | 337 (6.0) | 2528 (29.2) | <0.001 |
| Reason for terminal hospitalization |            |            | <0.001 |
| HCC                            | 0 (0) | 8664 (100) | <0.001 |
| Hepatic encephalopathy         | 1919 (34.4) | 2378 (27.5) | <0.001 |
| Septicemia                     | 2574 (46.1) | 1689 (19.5) | <0.001 |
| Pneumonia and respiratory failure | 2434 (43.6) | 1565 (18.1) | <0.001 |
| Esophageal varices             | 1230 (22.0) | 1750 (20.2) | 0.009 |
| Ascites                        | 1037 (18.6) | 1692 (19.5) | 0.157 |
| Renal failure                  | 1391 (24.9) | 1063 (12.3) | <0.001 |
| Peritonitis                    | 742 (13.3) | 691 (8.0) | <0.001 |
| Peptic ulcer disease           | 381 (6.8) | 532 (6.1) | 0.104 |
| Hepatorenal syndrome           | 365 (6.5) | 433 (5.0) | <0.001 |

* N (%) unless otherwise stated.

Table 2
Intensive care unit admission, cardiopulmonary resuscitation, and mechanical ventilation in terminal hospitalization (N = 14,247).

| Variable                        | ESLD only N = 5583 | ESLD + HCC N = 8664 | p-value |
|--------------------------------|--------------------|---------------------|---------|
| ICU admission                  |                    |                    | <0.001  |
| Yes                            | 3329 (59.6) | 1932 (22.3) | <0.001  |
| No                             | 2254 (40.4) | 6732 (77.7) | <0.001  |
| If Yes: LOS in ICU:            |                    |                    | <0.001  |
| median (IQR), range            | 6 (11), range 1–82 | 4 (6), range 1–60 | <0.001  |
| Cardiopulmonary resuscitation  |                    |                    | <0.001  |
| Yes                            | 618 (11.1) | 373 (4.3) | <0.001  |
| No                             | 4965 (88.9) | 8291 (95.7) | <0.001  |
| Mechanical ventilation         |                    |                    | <0.001  |
| Yes                            | 2028 (36.3) | 1080 (12.5) | <0.001  |
| No                             | 3555 (63.7) | 7594 (87.5) | <0.001  |

The factors associated with CPR and mechanical ventilation in terminal hospitalization were shown in supplemental material eTable 1 and eTable 2. Patients with pneumonia and respiratory failure had higher chances of receiving CPR during terminal hospitalization (aRR 2.1 [95% CI 1.0–4.2] in ESLD only group; 2.18 [95% 1.77–2.67] in ESLD plus HCC group), and those received palliative care before admission had lowest chances of receiving CPR (aRR 0.18 [0.08–0.44]; 0.09 [0.05–0.17]). As for mechanical ventilation, esophageal varices (aRR 1.28 [1.19–1.37]); 1.66 [1.48–1.85]), septicemia (aRR 1.09 [1.02–1.16]); 1.21 [1.07–1.36]), pneumonia and respiratory failure (aRR 1.85 [1.72–1.99]; 3.44 [3.08–3.84]) were associated with higher chances of receiving mechanical ventilation. Those who received palliative care before admission were less likely to receive mechanical ventilation (aRR 0.21 [0.14–0.32]; 0.14 [0.11–0.19]).

Discussion

This is the first population-based study evaluating the utilization of intensive care in end-of-life patients with ESLD, particularly in Taiwan where viral hepatitis is the leading cause of ESLD. The majority (60.8%) of our study population was comorbid with HCC. The findings showed a considerable difference between patients with and without comorbid HCC in terms of sociodemographic characteristics and intensive care utilization. Patients without HCC were less likely to receive palliative care prior to terminal hospitalization. Relatively more patients without HCC were admitted to ICU, receiving CPR or mechanical ventilation during terminal hospitalization, Etiology of alcoholic hepatitis, esophageal varices, septicemia, pneumonia and respiratory failure, and renal failure were associated with a higher probability of ICU admission in both groups. On the contrary, prior palliative care was associated with a lower chance of ICU admission, as well as receiving CPR or mechanical ventilation.

In our study, the utilization of intensive care was substantial in patients with ESLD during their terminal hospitalization (overall 39.6%), which was much higher than that of terminal cancer patients in Taiwan (17.8% in last month of life)[35]. The reasons why patients without HCC were more likely to be admitted to ICU (59.6%) during their terminal hospitalization (compared to those with comorbid HCC: 22.3%) need further investigation. It is possible that without the diagnosis of HCC, the disease trajectory was more unpredictable, and this uncertainty was more challenging for healthcare professionals to manage [36]. Consequently, the goals of care might mainly focus on curative treatment only and lead to intensive interventions or even futile management [6,11]. A similar finding was shown in a single-center study of patients with ESLD who had been denied liver transplantation. As high as 48% of the study population were subsequently admitted to ICU and more than half of them died in ICU [37].

Although we highlighted the intensive care utilization in patients with ESLD during their terminal hospitalization, it does not
necessarily imply that intensive care is “inappropriate” or “too aggressive.” As we illustrated in Table 1, some of the reasons for hospitalization seemed to be reversible at the beginning of the admission. Our findings reflect the challenges mentioned earlier: these patients might not be seen at the end of life, and the prognosis was difficult to predict. What are the potential clinical triggers for end-of-life discussion in these patients? Arvaniti et al. found that infections increase mortality four-fold and 30% of patients die within one month in patients with liver cirrhosis [38]. In addition to infection, Mazzarelli et al. proposed several clinical triggers for referral of ESLD patients to the palliative care service, including: those who are awaiting liver transplantation or are not eligible for transplantation, have had more than two hospital admissions with decompensated liver disease in previous one year, have complications related to ESLD (refractory ascites, hepatic encephalopathy), are older and more frail, have HCC, Child-Pugh classification C, Model For End-Stage Liver Disease (MELD) score ≥ 20, acute-on-chronic liver failure (ACLF) grade 2 or 3, or NECPAL CCOMS-ICO suggestion of high mortality risk [36,39,40]. Our findings suggest that palliative care should be initiated at the beginning of hospitalization or even earlier whenever there’s a need or these triggers happen. The coexistence of intensive care and palliative care in patients with ESLD may seem paradoxical in the past, but nowadays intensive care has been as concerned with palliation in many aspects [41–43].

Our study showed that prior palliative care was associated with less utilization of intensive care, CPR, and mechanical ventilation during the terminal hospitalization of patients with ESLD, which was similar to the results demonstrated by Patel et al. that inpatient

---

**Fig. 1.** Time trends of intensive care unit admission rate, with and without comorbid hepatocellular carcinoma, Taiwan 2010–2013. (ICU: intensive care unit. ESLD: end-stage liver disease. HCC: hepatocellular carcinoma.)

**Fig. 2.** Time trends of palliative care in the year before terminal hospitalization of study population, with and without comorbid hepatocellular carcinoma, Taiwan 2010–2013. (ESLD: end-stage liver disease. HCC: hepatocellular carcinoma.)
palliative care was associated with lower procedure burden [44]. Also, as shown in Figs. 1 and 2, while the proportion of palliative care before terminal hospitalization increased between 2010 and 2013, the utilization of ICU in terminal hospitalization decreased gradually in both groups of our study population. Although "early palliative care" has been shown to improve quality of life and to reduce symptom intensity in cancer patients [45], there is still a lack of evidence to confirm the potential of early palliative care and advance care planning.

Regarding clinical factors, esophageal varices was the only complication of decompensation that was consistently associated with higher intensive care utilization. Esophageal varices bleeding is characterized as vomiting large amounts of blood and probable sudden loss of consciousness, and these patients deteriorate abruptly. By contrast, other complications develop in a subtle way and the progression is relatively slow. That may be the reason why esophageal varices were associated with higher chance of ICU admission (in both groups), CPR (in ESLD only group), and mechanical ventilation (in both groups). Not surprisingly, septicemia, pneumonia and respiratory failure, and renal failure were associated with higher probability of ICU admission and mechanical ventilation. In these cases, preventive strategies may be more helpful than picking up the pieces in the end. In addition, the factors identified in our study may contribute to identifying the subsets of patients with ESLD who are most likely to benefit from palliative care and advance care planning.

Our study has several limitations. First, the causal relationship between intensive care utilization and explanatory factors cannot be easily established in this retrospective cohort study. Second, some findings related to socio-demographic factors may be subject to ecological fallacy, and the hospital-level factors (e.g. hospital size, ownership, hospital teaching status, infrastructure of intensive care and palliative care) may contribute to the accessibility of standard care as well as palliative care in these patients need further investigation.

Table 3
Factors associated with intensive care unit admission in terminal hospitalization.

| Variable                          | ESLD only (N = 5583) | ESLD+HCC (N = 8664) |
|----------------------------------|----------------------|---------------------|
|                                  | Unadjusted RR (95% CI) | Adjusted RR (95% CI) | Unadjusted RR (95% CI) | Adjusted RR (95% CI) |
| Age of death (ref: <.45)         | 0.96 (0.91–1.02)      | 0.98 (0.93–1.03)     | 1.13 (0.92–1.39)      | 1.13 (0.94–1.35)     |
| 45–54                            | 0.96 (0.91–1.02)      | 0.98 (0.93–1.03)     | 1.13 (0.92–1.39)      | 1.13 (0.94–1.35)     |
| 55–64                            | 0.88 (0.83–0.93)      | 0.93 (0.88–0.99)     | 1.03 (0.85–1.26)      | 1.05 (0.88–1.26)     |
| 65–74                            | 0.74 (0.69–0.79)      | 0.81 (0.75–0.88)     | 0.95 (0.78–1.16)      | 0.99 (0.83–1.18)     |
| 75–84                            | 0.65 (0.60–0.71)      | 0.72 (0.65–0.79)     | 0.88 (0.71–1.08)      | 0.92 (0.76–1.11)     |
| 85+                              | 0.54 (0.45–0.66)      | 0.60 (0.50–0.73)     | 0.87 (0.67–1.15)      | 0.91 (0.71–1.17)     |
| Sex (ref: female)                | 1.18 (1.12–1.24)      | 0.98 (0.93–1.04)     | (not included)        |                     |
| Male                             | 0.97 (0.91–1.02)      | 0.97 (0.92–1.02)     | 0.95 (0.86–1.06)      | 1.02 (0.93–1.12)     |
| Year of death (ref: 2010)        | 0.95 (0.90–1.01)      | 0.97 (0.92–1.02)     | 0.83 (0.74–0.92)      | 1.05 (0.95–1.16)     |
| 2011                             | 0.87 (0.82–0.93)      | 0.95 (0.90–1.01)     | 0.86 (0.77–0.97)      | 1.15 (1.04–1.28)     |
| 2012                             | 0.87 (0.82–0.93)      | 0.95 (0.90–1.01)     | 0.86 (0.77–0.97)      | 1.15 (1.04–1.28)     |
| Region of residence (ref: Northern) | 1.08 (1.02–1.14)  | 1.06 (1.00–1.12)     | 1.36 (1.22–1.51)      | 1.29 (1.17–1.42)     |
| Middle                           | 0.94 (0.89–0.99)      | 0.95 (0.90–1.00)     | 0.99 (0.90–1.08)      | 1.03 (0.94–1.13)     |
| Southern                         | 1.14 (1.05–1.25)      | 1.08 (1.00–1.18)     | 0.96 (0.75–1.22)      | 1.11 (0.89–1.39)     |
| Eastern and offshore islands     | 1.01 (0.91–1.12)      | 0.95 (0.86–1.05)     | 1.36 (1.07–1.73)      | 1.38 (1.11–1.73)     |
| Not mentioned                    | 1.22 (1.25–1.40)      | 1.09 (1.02–1.16)     | 1.65 (1.44–1.88)      | 1.29 (1.14–1.46)     |
| Etiology (ref: viral only)       | 1.19 (1.11–1.27)      | 1.03 (0.96–1.10)     | 1.40 (1.25–1.57)      | 1.16 (1.04–1.29)     |
| Alcoholic only                   | 1.10 (1.02–1.18)      | 1.08 (1.01–1.16)     | 1.33 (1.20–1.48)      | 1.22 (1.11–1.35)     |
| Mixed (viral and alcoholic)      | 0.99 (0.93–1.06)      | 1.03 (0.97–1.09)     | (ref group)           | (ref group)          |
| Not mentioned or others          | 0.92 (0.86–0.98)      | 1.01 (0.95–1.07)     | 1.05 (0.94–1.17)      | 1.06 (0.96–1.17)     |
| Comorbidity (ESLD deducted, ref: 0, 1 each) | 0.84 (0.77–0.91)  | 0.86 (0.89–1.04)     | 1.16 (1.03–1.30)      | 1.15 (1.04–1.29)     |
| 1                                | 0.82 (0.74–0.91)      | 0.87 (0.88–1.07)     | 1.24 (1.09–1.42)      | 1.22 (1.08–1.39)     |
| 2                                | 0.31 (0.25–0.39)      | 0.38 (0.31–0.47)     | 0.20 (0.17–0.23)      | 0.24 (0.21–0.29)     |
| Prior palliative care (ref: no)  | 0.77 (0.74–0.82)      | 0.87 (0.83–0.91)     | 0.69 (0.63–0.77)      | 0.86 (0.78–0.94)     |
| Reasons for terminal hospitalization | 0.65 (0.60–0.70)  | 0.76 (0.70–0.82)     | 0.56 (0.49–0.64)      | 0.70 (0.62–0.80)     |
| Hepatic encephalopathy (ref: no) | 1.17 (1.12–1.23)      | 1.13 (1.08–1.18)     | 1.84 (1.70–2.00)      | 1.78 (1.64–1.92)     |
| Ascites (ref: no)                | 0.76 (0.68–0.86)      | 0.87 (0.79–0.98)     | 0.71 (0.57–0.89)      | 0.89 (0.72–1.10)     |
| Esophageal varices (ref: no)     | 1.22 (1.17–1.27)      | 1.12 (1.07–1.16)     | 1.51 (1.39–1.65)      | 1.36 (1.25–1.48)     |
| Hepatorenal syndrome (ref: no)   | 1.40 (1.35–1.47)      | 1.26 (1.21–1.31)     | 2.64 (2.45–2.84)      | 2.09 (1.94–2.25)     |
| Septicemia (ref: no)             | 1.19 (1.13–1.25)      | 1.10 (1.05–1.15)     | 1.48 (1.33–1.65)      | 1.38 (1.25–1.52)     |
palliative care, ICU bed availability) were not contained in our dataset. Third, although the provision of ICU admission was mainly initiated by physicians, the understanding of disease status, the willingness to receive further treatments, and personal preferences were still important. The physicians’ attitude and concept of palliative care also vary across different healthcare settings. All these factors were not available in the NHIRD. Forth, there is a lack of other relevant clinical factors, such as severity of liver disease, results of clinical exams or laboratory findings, or previous therapies for HCC. However, according to our inclusion criteria by using RCIPD, our study population were relatively homogeneous (at least Child-Turcotte-Pugh class B and mostly class C). Fifth, there was no data showing who were listed for liver transplantation in our dataset. In fact, the organ donation rate of Taiwan has been around 4-7 to 7.2 per million people per year, which is much lower than that in Western countries [50]. In our study, we excluded those who had received liver transplantation because their healthcare utilization was markedly different from other ESLD patients. Finally, the NHIRD was not established for end-of-life research, so it was difficult to access the patients’ symptoms or quality of life as well as the quality of palliative care, which may be related to the utilization of intensive care. The findings of our study should be interpreted with caution and correlated with clinical context.

In conclusion, the intensive care utilization by patients with ESLD in their terminal hospitalization was substantial in Taiwan. Prior palliative care is associated with a lower probability of intensive care utilization during terminal hospitalization. Those who are not comorbid with HCC need more attention especially in terms of their palliative care needs, choices regarding intensive care, and their healthcare utilization.

Acknowledgements
Not applicable

Declarations
Availability of data and material
According to the data agreement we signed with the National Health Research Institutes of Taiwan, we are not allowed to share our data.

Competing interests
The authors declare that they have no potential competing interests.

Funding
We thank Ministry of Education of Taiwan for educational grant for JKP. This study is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions
JKP and WG designed the study. HHC and JKP applied for the data-set. JKP performed analysis and wrote the first draft, supervised by WG. HGC gave advice related to the healthcare system and clinical experience in Taiwan. JJH provided clinical academic input in palliative care. JKP, WG and HHC had full access to all data in the study. All authors reviewed the findings, agreed on the interpretation, contributed to writing the paper, and read and approved the final version.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2020.100357.

References

[1] Tsiochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383(9930):1749–61.
[2] Mokdad AA, Lopez AD, Shahnaz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMJ Med 2014;12:145.
[3] WHO. Age-standardized death rates liver cirrhosis (15+ years) per 100,000 population, 2012. World Health Organization; 2014.
[4] European social statistics 2013. Luxembourg: European Union; 2013.
[5] Cox North P, Doorenbos A, Shannon SE, Scott JT, Curtis JS. The transition to end-of-life care in end-stage liver disease. J Hosp Palliat Nurs 2013;15(4):209–15.
[6] Elliott K, Osinowo A, Pring A. Deaths from liver disease: Implications for end of life care in England. National End of Life Care Intelligence Network 2012.
[7] Mariño RT, Duarte H, Giria J, Nunes J, Ferraíra A, Velosa J. The burden of alcoholism in fifteen years of cirrhosis hospital admissions in Portugal. Liver Int 2015;35(3):746–55.
[8] Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011;54(2):381–92.
[9] Yang JF, Lin CI, Huang JF, Dai CY, Lin WT, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. The Kaohsiung journal of medical sciences 2009;25(1):6–9.
[10] Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2(826):1129–33.
[11] Langberg KM, Taddéi TH. Balancing quality with quantity: The role of palliative care in managing decompen-sated cirrhosis. Hepatology 2016;64(4):1014–6.
[12] Cardona-Morrell M, Kim J, Turner RM, Anstey M, Mitchell IA, Hillman K. Non-beneficial treatments in hospital at the end of life: a systematic review on extent of the problem. Int J Qual Health Care 2016;28(4):456–69.
[13] Tang ST, Wu SC, Hung YN, Chen JS, Huang EW, Liu WT. Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J Clin Oncol 2009;27(27):4613–8.
[14] Bruck E, Schandl A, Bottai M, Sackey P. The impact of sespits, delirium, and psycho-logical distress on self-rated cognitive function in ICU survivors–a prospective cohort study. J Intensive Care 2018;6(1):2.
[15] Probst DR, Custin JL, Goodman LF, Lorenz A, Wells-Doctor Gregorio SM. ICU versus Non-ICU Hospital Death: Family Member Complicated Grief, Posttraumatic Stress, and Depressive Symptoms. J Palliat Med 2016;19(4):387–93.
[16] Fridh I. Caring for the dying patient in the ICU—the past, the present and the future. Intensive Crit Care Nurs 2014;30(6):306–11.
[17] Verhaeghe S, Defloor T, Van Zuuren F, Dujnsehle M, Grypdonck M. The needs and experiences of family members of adult patients in an intensive care unit: a review of the literature. J Clin Nurs 2005;14(4):501–9.
[18] Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: “too well for transplant, too sick for life.” JAMA 2006;295(18):2168–76.
[19] Potosky J, Currie M, Buss M, Chittenden E. Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med 2014;17(11):1271–7.
[20] Rakowski MO, Volk MS. Palliative care for patients with end-stage liver disease: An overview. Clin Liver Dis (Hoboken) 2015;6(1):19–21.
[21] National Health Insurance Administration. Palliative Care Services Open to Terminally Ill Non-cancer Patients in Eight Newly Added Categories, Officially Covered by National Health Insurance since September 1st, 2009 2009[Available from: https://www.nhi.gov.tw/english/News_Content.aspx?n=999611B865DC433B&msno=001EAF8EB16E7DF6FA07374BCDCC628]
[22] von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JG, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147(8):737–42.
[23] Wu CY, Chan FK, Wu MS, Kuo KW, Wang CB, Tao CR, et al. Histamine-2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010;139(4):1165–71.
[24] Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gas-troenterology 2009;137(5):1641–8 e1–2.
[25] Wu CY, Wu MS, Kuo KW, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010;28(18):2952–7.
[26] Lai SW, Liao RF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28(6):485–92.
[27] Lai SW, Liao RF, Lin CY, Lin CL, Sung FC. Statins on the risk of gastric cancer: a population-based observational study in Taiwan. Am J Gastroenterol 2013;108(1):147–59.
[28] Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoeconomics and drug safety 2011;20(3):236–42.
[30] Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 1987;40(5):373–83.

[31] Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159(7):702–6.

[32] Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC medical research methodology 2003;3:21.

[33] Ranganathan P, Aggarwal R, Pramesh CS. Common pitfalls in statistical analysis: Odds versus risk. Perspectives in clinical research 2015;6(4):222–4.

[34] Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med 1998;55(4):272–7.

[35] Chiang JK, Lee YC, Kao YH. Trend analysis of end-of-life care between hospice and nonhospice groups of cancer patients in Taiwan for 2002–11. Medicine (Baltimore) 2017;96(34):e7825.

[36] Mazzarelli C, Prentice WM, Heneghan MA, Belli LS, Agarwal K, Cannon MD. Palliative care in end-stage liver disease: Time to do better? Liver Transpl 2018;24(7):961–8.

[37] Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol 2014;12(4):692–8.

[38] Arvaniti V, D’Amico G, Fede G, Manousoy P, Tsiochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139(4):1246–56, 56 e1–5.

[39] Gomez-Batiste X, Martinez-Munoz M, Blay C, Amblas J, Vila I, Costa X, et al. Utility of the NECPAL CCOMS-ICO(c) tool and the Surprise Question as screening tools for early palliative care and to predict mortality in patients with advanced chronic conditions: A cohort study. Palliat Med 2017;31(8):754–63.

[40] Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62(1):243–52.

[41] Cook D, Rucker G. Dying with dignity in the intensive care unit. N Engl J Med 2014;370;26:2506–14.

[42] Ho A, Tsai DF. Making good death more accessible: end-of-life care in the intensive care unit. Intensive care medicine 2016;42(8):1258–60.

[43] Truong RD, Campbell ML, Curtis JR, Haas CE, Luce JM, Rubenfeld GD, et al. Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American College [corrected] of Critical Care Medicine. Critical care medicine 2008;36(3):953–63.

[44] Patel AA, Walling AM, Ricks-Oldje J, May FP, Saab S, Wenger N. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life. Clin Gastroenterol Hepatol 2017;15(10):1612–9 e4.

[45] Haun MW, Estel S, Rucker G, Friederich HC, Villalobos M, Thomas M, et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 2017;6:CD011129.

[46] Beck KR, Pantilat SZ, O’Riordan DL, Peters MG. Use of Palliative Care Consultation for Patients with End-Stage Liver Disease: Survey of Liver Transplant Service Providers. J Palliat Med 2016;19(8):836–41.

[47] Low ITS, Rohde G, Pitteroud K, Candy B, Davis S, Marshall A, et al. Supportive and palliative care in patients with cirrhosis: International systematic review of the perspective of patients, family members and health professionals. J Hepatol 2018;69(6):1260–73.

[48] Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855–9.

[49] Edelman EJ, Fiellin DA. Alcohol Use. Ann Intern Med 2016;165(5):379–80.

[50] Kuo WT, Hsia CT, Loong CC, Liao CL, Tsai HJ, Tieng HS, et al. Outcome of foreign residents undergoing deceased donor liver transplantation in China: a single-center experience in Taiwan. Liver Transpl 2009;15(11):1579–85.